

CLINICAL PHARMACOLOGY and THERAPEUTICS

Editor

Walter Modell, M.D.

Associate Editor

Marcus M. Reidenberg, M.D.

Editorial Board

Alvito P. Alvares, Ph.D.
Wilbert S. Aronow, M.D.
Arthur J. Atkinson, Jr., M.D.
Daniel L. Azarnoff, M.D.
Frank M. Berger, M.D., D.Sc.
Karl H. Beyer, Jr., M.D., Ph.D.
Hylan A. Bickerman, M.D.
Terrence F. Blaschke, M.D.
Donald B. Calne, M.D.
Edward A. Carr, Jr., M.D.
Allan H. Conney, Ph.D.
T. S. Danowski, M.D.
Arthur C. DeGraff, M.D.
Peter Dineen, M.D.
Edward F. Domino, M.D.
Alvan R. Feinstein, M.D.
Vladimir Fencl, M.D.
Robert B. Forney, Ph.D.
Emil Frei, III, M.D.
Milo Gibaldi, Ph.D.
Norton J. Greenberger, M.D.
Leo E. Hollister, M.D.
Bartholomew P. Hsi, Ph.D.
Murray E. Jarvik, M.D.
Werner Kalow, M.D.

Stanley A. Kaplan, Ph.D.
Arthur S. Keats, M.D.
Richard H. Kessler, M.D.
Kenneth G. Kohlstaedt, M.D.
Henn Kutt, M.D.
Louis Lasagna, M.D.
Louis Lemberger, M.D., Ph.D.
Gerhard Levy, Pharm.D.
T. A. Loomis, M.D., Ph.D.
David T. Lowenthal, M.D.
Daniel S. Lukas, M.D.
Arno G. Motulsky, M.D.
Alan S. Nies, M.D.
Laurence G. Raiz, M.D.
R. K. Richards, M.D.
David G. Shand, M.B., Ph.D.
Albert Sjoerdsma, M.D., Ph.D.
Jay Tepperman, M.D.
Max Tishler, Ph.D.
Leroy D. Vandam, M.D.
Elliot S. Vesell, M.D.
Louis Weinstein, M.D.
John G. Wagner, Ph.D.
E. Leong Way, Ph.D.

Volume 31, January-June, 1982

The C. V. Mosby Company, St. Louis

Volume 31
Copyright © 1982 by
The C. V. Mosby Company

All rights reserved

Printed in the United States of America

Index to volume 31

Author index

A

- Abbott FS: *see* Orr et al, 642
Abernethy DR, Divoll M, Greenblatt DJ, Ameer B:
Obesity, sex, and acetaminophen disposition, 783
—*see* Divoll et al, 151
Actor P: *see* Dubb et al, 516
Adir J, Miller AK, Vestal RE: Effects of total plasma concentration and age on tolbutamide plasma protein binding, 488
Agoston S: *see* Uges et al, 587
Alexander F: *see* Dubb et al, 516
Amann FW: *see* Kiowski et al, 677
Ameer B: *see* Abernethy et al, 783
—*see* Divoll et al, 151
Amon KW: *see* Crawford et al, 459
Ampulski RS: *see* Yakatan et al, 402
Amsterdam EA: *see* Awan et al, 290
Anderson KE: *see* Pantuck et al, 533
Aronow WS: *see* Weber et al, 572
Atu-Taylor LC: *see* Woolhouse and Atu-Taylor, 377
Aurecchia SA: *see* Griffing et al, 56, 713
Aust PE: *see* Belz et al, 548
Awan NA, Hermanovich J, Vera Z, Amsterdam EA, Mason DT: Cardiocirculatory actions of trimazosin and sodium nitroprusside in ischemic heart disease, 290

B

- Bachur NR, Collins JM, Kelley JA, Kaplan RS, Van Echo DA, Whitacre M: Diaziquone, 2,5-diaziridinyl-3,6-bis(carboethoxyamino)-1,4-benzoquinone, plasma and cerebrospinal fluid kinetics, 650
Bah H: *see* Richer et al, 579
Barson WJ: *see* Nahata et al, 528
Bauer LA, Blouin RA: Age and phenytoin kinetics in adult epileptics, 301
—Brown T, Gibaldi M, Hudson L, Nelson S, Raisys V, Shea JP: Influence of long-term infusions on lidocaine kinetics, 433
—Harris C, Wilensky AJ, Raisys VA, Levy RH: Ethosuximide kinetics: possible interaction with valproic acid, 741

- Belz GG, Doering W, Aust PE, Heinz M, Matthews J, Schneider B: Quinidine-digoxin interaction: cardiac efficacy of elevated serum digoxin concentration, 548
Benedict JJ: *see* Yakatan et al, 402
Bengtsson B, Fagerstrom P-O: Extrapulmonary effects of terbutaline during prolonged administration, 726
Benjamin RS: *see* Savaraj et al, 312
Benowitz NL: *see* Pond et al, 139
Berlin CM Jr, Vesell ES: Antipyrine disposition in milk and saliva of lactating women, 38
Bertilsson L: *see* Eichelbaum et al, 184
Bianchini JR: *see* Leier et al, 89
Bigelow GE: *see* McCaul et al, 753
Bjornsson T, Wolfram KM, Kitchell BB: Heparin kinetics determined by three assay methods, 104
—*see* Mahony et al, 330
Blair AD: *see* Counts et al, 662
Block AJ: *see* Ronfeld et al, 384
Blouin RA: *see* Bauer and Blouin, 301
Bock JL, Giller E, Gray S, Jatlow P: Steady-state plasma concentrations of *cis*- and *trans*-10-OH amitriptyline metabolites, 609
Bojsen J: *see* Kølendorf and Bojsen, 494
Bolanowska W: *see* Paigen et al, 144
Booth RJ, Wilson JD, Bullock JY: β -Adrenergic-receptor blockers and antinuclear antibodies in hypertension, 555
Branch RA: *see* Verbeeck et al, 719
Breen KJ, Bury R, Desmond PV, Mashford ML, Morphett B, Westwood B, Shaw RG: Effects of cimetidine and ranitidine on hepatic drug metabolism, 297
Brewer DD: *see* Weber et al, 572
Brine DR: *see* Cook et al, 625, 635
Brown MJ, Lhost FJM, Zamboulis C, Ind PW, Jenner DA, Dollery CT: Estimation of sympathetic activity in essential hypertension, 16
Brown T: *see* Bauer et al, 433
Bubrick MP: *see* Pancorbo et al, 83
Buckner J: *see* Wilkin et al, 478
Buhler FR: *see* Kiowski et al, 677
Bullock JY: *see* Booth et al, 555
Burgess M: *see* Savaraj et al, 312
Bury R: *see* Breen et al, 297
Buskin JN: *see* Upton et al, 705
Byck R: *see* Zahler et al, 775

- Graham RM, Campbell WB, Jackson EK: Effects of short-term beta blockade on blood pressure, plasma thromboxane B₂, and plasma and urinary prostaglandins E₂ and F_{2α} in normal subjects, 324
- Granneman GR, Sennello LT, Sonders RC, Wynne B, Thomas EW: Cefsulodin kinetics in healthy subjects after intramuscular and intravenous injection, 95
- see Gibson et al, 602
- Gray S: see Bock et al, 609
- Greco FA: see Hande et al, 669
- Greenblatt DJ: see Abernethy et al, 783
- see Divoll et al, 151
- see Shader et al, 180
- Greijdanus B: see Uges et al, 587
- Griffing GT, Cole AG, Aurecchia SA, Sindler BH, Komanicky P, Melby JC: Amiloride in primary aldosteronism, 56
- Komanicky P, Aurecchia SA, Sindler BH, Melby JC: Amiloride in Bartter's syndrome, 713
- Grigoleit H-G: see Muller et al, 339
- Grossman SH, Davis D, Kitchell BB, Shand DG, Routledge PA: Diazepam and lidocaine plasma protein binding in renal disease, 350
- Gugler R, Rohner H-G, Somogyi AA: Gastric acid inhibition and omepridine kinetics in duodenal ulcer, 501
- Gustafson JH: see Dujovne et al, 187

H

- Hadj-Aissa A: see Chau et al, 770
- Hande KR, Stein RS, McDonough DA, Greco FA, Wolff SN: Effects of high-dose cytarabine, 669
- Harmatz J: see Shader et al, 180
- Harris C: see Bauer et al, 741
- Harrison DC: see Kates et al, 427
- Harrison IR: see McInnes et al, 317
- Harrison TS: see Luderer et al, 305
- Hayes AH Jr: see Luderer et al, 305
- Heinz M: see Belz et al, 548
- Hendrickson JA: see Kannan et al, 438
- Hermanovich J: see Awan et al, 290
- Herrin WF: see Hurwitz et al, 168
- Hill JM: see Cook et al, 625
- Hökfelt B: see Manhem et al, 445
- Houben H, Thien T, van't Larr A: Effect of low-dose epinephrine infusion on hemodynamics after selective and nonselective β -blockade in hypertension, 685
- Hudson L: see Bauer et al, 433
- Hulthén L: see Kiowski et al, 677
- Hurwitz A, Robinson RG, Herrin WF, Christie J: Oral anticholinergics and gastric emptying, 168
- Huss P: see Leier et al, 89

I

- Inaba T: see Vinks et al, 23

- Ind PW: see Brown et al, 16
- Inturrisi CE, Colburn WA, Verebey K, Dayton HE, Woody GE, O'Brien CP: Propoxyphene and norpropoxyphene kinetics after single and repeated doses of propoxyphene, 157

J

- Jackson EK: see Graham et al, 324
- Jacob P III: see Pond et al, 139
- Jacoby JA: see Scharf and Jacoby, 175
- Jarboe CH: see May et al, 656
- Jatlow P: see Bock et al, 609
- see Zahler et al, 775
- Jeffcoat AR: see Cook et al, 625
- Jenden DJ: see Jope et al, 483
- Jenner DA: see Brown et al, 16
- Jones RM: see Upton et al, 705
- Jope RS, Domino EF, Mathews BN, Sitaram N, Jenden DJ, Ortiz A: Free and bound choline blood levels after phosphatidylcholine, 483
- Jostell KG: see Calil et al, 522
- Jusko WJ: see Potter et al, 393

K

- Kalow W: see Vinks et al, 23
- Kalra J: see Gault et al, 695
- Kamm B: see Day et al, 733
- Kannan R, Nademanee K, Hendrickson JA, Rostami HJ, Singh BN: Amiodarone kinetics after oral doses, 438
- Kaplan RS: see Bachur et al, 650
- Kapp R: see Wilkin et al, 478
- Kappas A: see Pantuck et al, 533
- Kates RE, Harrison DC, Winkle RA: Metabolite cumulation during long-term oral encainide administration, 427
- Kawai S, Ogawa K, Satake T: Erythrocyte digoxin concentration, 541
- Keeney RE: see Laskin et al, 594
- Kelley JA: see Bachur et al, 650
- Kennedy GT: see Crawford et al, 459
- Khouw V: see Giles et al, 77
- see Naranjo et al, 746
- Kinsman RA: see Dirks and Kinsman, 413
- Kiowski W, van Brummelen P, Hulthén L, Amann FW, Buhler FR: Antihypertensive and renal effects of captopril in relation to renin activity and bradykinin-induced vasodilation, 677
- Kirsten EB: see McAllister and Kirsten, 418
- Kitanaka I, Ross RJ, Cutler NR, Zavadi AP III, Potter WZ: Altered hydroxydesipramine concentrations in elderly depressed patients, 51
- Kitchell BB: see Björnsson et al, 104
- see Grossman et al, 350
- Knowles JA: see Chiang et al, 509
- Køglendørf K, Bojsen J: Kinetics of subcutaneous NPH insulin in diabetics, 494

- Komanicky P: *see* Griffing et al, 56, 713
Konno K: *see* Nuotto et al, 68
Krasny HC: *see* Laskin et al, 594

L

- LaCorte WS, McMurtrey JJ, Chapman J, Gotzkowsky S, Chang-Chien S, Ryan JR, McMahon FG: A simple controlled method for the clinical evaluation of antidiarrheal drugs, 766
Lalka D: *see* Edwards et al, 62
Langlois G: *see* Rangno et al, 8, 564
Lasagna L: Will all new drugs become orphans, 285 (Commentary)
Laskin OL, Longstreth JA, Whelton A, Rocco L, Leitman PS, Krasny HC, Keeney RE: Acyclovir kinetics in end-stage renal disease, 594
Leier CV, Nelson S, Huss P, Bianchine JR, Olukotun AY, Taylor CR, Salzburg DS: Intravenous pirbuterol, 89
Leitman PS: *see* Laskin et al, 594
Levy RH: *see* Bauer et al, 741
Lhoste FJM: *see* Brown et al, 16
Liebson I: *see* McCaul et al, 753
Lipson JL: *see* Weber et al, 572
Liu E, Rubenstein M: Phenytoin removal by plasmapheresis in thrombotic thrombocytopenic purpura, 762
Long JP: *see* Giles et al, 559
Longerich L: *see* Gault et al, 695
Longstreth JA: *see* Laskin et al, 594
Loo TL: *see* Savaraj et al, 312
Lorenzo B: *see* Drayer et al, 45
Lu K: *see* Savaraj et al, 321
Ludden TM, Crawford MH: *N*-Acetylprocainamide kinetics after single and repeated oral doses, 343
—*see* Crawford et al, 459
Luderer JR, Demers LM, Harrison TS, Hayes AH Jr: Converting enzyme inhibition with captopril in patients with primary hyperaldosteronism, 305
Lutterodt A: *see* Rangno et al, 8

M

- McAllister RG Jr, Kirsten EB: The pharmacology of verapamil. IV. Kinetic and dynamic effects after single intravenous and oral doses, 418
McCaul ME, Bigelow GE, Stitzer ML, Liebson I: Short-term effects of oral methadone in methadone maintenance subjects, 753
McDonough DA: *see* Hande et al, 669
McInnes GT: Relative potency of amiloride and spironolactone in healthy man, 472
—Perkins RM, Shelton JR, Harrison IR: Dose-response relationships for spironolactone at steady state, 317
McKinstry DN: *see* Duchin et al, 452
McMahon FC: *see* LaCorte et al, 766
McMurtrey JJ: *see* LaCorte et al, 766

- Magrini F: *see* Niarchos and Magrini, 370
Mahony C, Wolfram KM, Cocchetto DM, Bjornsson TD: Dipyridamole kinetics, 330
Manhem P, Paalzow L, Hökfelt B: Plasma clonidine in relation to blood pressure, catecholamines, and renin activity during long-term treatment of hypertension, 445
Mashford ML: *see* Breen et al, 297
Mason DT: *see* Awan et al, 290
Mathews BN: *see* Jope et al, 483
Mathieu M: *see* Richer et al, 579
Matthews J: *see* Belz et al, 548
Mattila MJ: *see* Nuotto et al, 68
May DC, Jarboe CH, VanBakel AB, Williams WM: Effects of cimetidine on caffeine disposition in smokers and nonsmokers, 656
Melby JC: *see* Griffing et al, 56, 713
Meyer BH: *see* Muller et al, 339
Miaskiewicz SL, Shively CA, Vesell ES: Sex differences in absorption kinetics of sodium salicylate, 30
Migdalof BH: *see* Duchin et al, 452
Miller AK: *see* Adir et al, 488
Miller KW: *see* Pancorbo et al, 83
Morphett B: *see* Breen et al, 297
Morrison G: *see* Chiang et al, 509
Muller FO, Meyer BH, van Reenen OR, Grigoleit H-G: Potassium balance in piretanide and digoxin treatment, 339

N

- Nademanee K: *see* Kannan et al, 438
Nahata MC, Durrell DE, Barson WJ: Moxalactam epimer kinetics in children, 528
Naranjo CA, Khouw V, Sellers EM: Nonfatty acid-modulated variations in drug binding due to heparin, 746
Nelson S: *see* Bauer et al, 433
—*see* Leier et al, 89
Niarchos AP, Magrini F: Hemodynamic effects of diuretics in patients with marked peripheral edema and mild hypertension, 370
Nuotto E, Mattila MJ, Seppälä T, Konno K: Coffee and caffeine and alcohol effects on psychomotor function, 68

O

- O'Brien CP: *see* Inturrisi et al, 157
Ogawa K: *see* Kawai et al, 541
Oklukotun AY: *see* Leier et al, 89
Onstad G: *see* Pancorbo et al, 83
O'Rourke RA: *see* Crawford et al, 459
Orr JM, Abbott FS, Farrell K, Ferguson S, Sheppard I, Godolphin W: Interaction between valproic acid and aspirin in epileptic children: serum protein binding and metabolic effects, 642
Orrego H: *see* Giles et al, 559
Ortiz A: *see* Jope et al, 483
Otton SV: *see* Vinks et al, 23

P

- Paalzow L: *see* Manhem et al, 445
 Paigen B, Ward E, Steenland K, Bolanowska W, Gessner T, Chang RL, Wood AW, Conney AH: Absence of seasonal variation in antipyrine metabolism, 144
 Painter MJ: *see* Pitlick et al, 466
 Pancorbo S, Bubrick MP, Chin TWF, Miller KW, Onstad G: Cimetidine dynamics after single intravenous doses, 83
 Pantuck CB: *see* Pantuck et al, 533
 Pantuck EJ, Pantuck CB, Anderson KE, Conney AH: Cigarette smoking and chlorpromazine disposition and actions, 533
 Patwardhan RV: *see* Verbeek et al, 719
 Paulus HE: *see* Day et al, 733
 Perez-Reyes M, Di Guiseppe S, Davis KH, Schindler VH, Cook CE: Comparison of effects of marihuana cigarettes of three different potencies, 617
 — *see* Cook et al, 625, 635
 Perkins RM: *see* McInnes et al, 317
 Pirikitakuhl P: *see* Pitlick et al, 466
 Pitkin D: *see* Dubb et al, 516
 Pitlick WH, Pirikitakuhl P, Painter MJ, Wessel HB: Effects of glycerol and hyperosmolality on intracranial pressure, 466
 Pond SM, Tong TG, Benowitz NL, Jacob P III, Rigod J: Lack of effect of diazepam on methadone metabolism in methadone-maintained addicts, 139
 Potter WZ, Calil HM, Sutfin TA, Zavadil AP III, Jusko WJ, Rapoport J, Goodwin FK: Active metabolites of imipramine and desipramine in man, 393
 — *see* Calil et al, 522
 — *see* Kitanaka et al, 51
 Poynor WJ: *see* Yakatan et al, 402
 Pozet N: *see* Chau et al, 770

Q

- Quin GD: *see* Cook et al, 635

R

- Raisys V: *see* Bauer et al, 433
 Raisys VA: *see* Bauer et al, 741
 Rangno RE, Langlois S, Lutterodt A: Metoprolol withdrawal phenomena: mechanism and prevention, 8
 —, — Stewart J: Cardiac hyper- and hyporesponsiveness after pindolol withdrawal, 564
 Rapoport J: *see* Potter et al, 393
 Reidenberg MM: *see* Drayer et al, 45
 Ricci BA: *see* Weber et al, 572
 Richer C, Mathieu M, Bah H, Thuille C, Duroux P, Giudicelli J-F: Theophylline kinetics and ventilatory flow in bronchial asthma and chronic airflow obstruction: influence of erythromycin, 579
 Riegelman S: *see* Tang-Liu et al, 358
 Rigod J: *see* Pond et al, 139

- Robinson RG: *see* Hurwitz et al, 168
 Rocco L: *see* Laskin et al, 594
 Roe R: *see* Day et al, 733
 Rohner H-G: *see* Gugler et al, 501
 Romankiewicz J: *see* Drayer et al, 45
 Ronfeld RA, Wolshin EM, Block AJ: On the kinetics and dynamics of tocinide and its metabolites, 384
 Ross RJ: *see* Kitanaka et al, 51
 Rostami HJ: *see* Kannan et al, 438
 Routledge PA: *see* Grossman et al, 350
 Rubenstein M: *see* Liu and Rubenstein, 762
 Ruelius HW: *see* Chiang et al, 509
 Ryan JR: *see* LaCorte et al, 766

S

- Salzburg DS: *see* Leier et al, 89
 Satake T: *see* Kawai et al, 541
 Savaraj N, Lu K, Valdivieso M, Burgess M, Umsawadi T, Benjamin RS, Loo TL: Clinical kinetics of 1,4-dihydroxy-5,8-bis[[2-[(2-hydroxyethyl)amino]-ethyl]amino]-9,10-anthracenedione, 312
 Säwe J: *see* Eichelbaum et al, 184
 Scaf AHJ: *see* Uges et al, 587
 Scharf MB, Jacoby JA: Lorazepam—Efficacy, side effects, and rebound phenomena, 175
 Schindler VH: *see* Perez-Reyes et al, 617
 Schneider B: *see* Belz et al, 548
 Sellers EM: *see* Giles et al, 77, 559
 — *see* Naranjo et al, 746
 Sennello LT: *see* Gibson et al, 602
 — *see* Granneman et al, 95
 Seppälä T: *see* Nuotto et al, 68
 Shader RI, Ciraulo DA, Greenblatt DJ, Harmatz J: Steady-state plasma desmethyldiazepam during long-term clorazepate use: effect of antacids, 180
 Shand DG: *see* Grossman et al, 350
 Shaw RG: *see* Breen et al, 297
 Shea JP: *see* Bauer et al, 433
 Shelton JR: *see* McInnes et al, 317
 Sheppard I: *see* Orr et al, 642
 Shively CA: *see* Miaskiewicz et al, 30
 Sindler BH: *see* Griffing et al, 56, 713
 Singh BN: *see* Kannan et al, 438
 Singhvi SM: *see* Duchin et al, 452
 Sitaram N: *see* Jope et al, 483
 Slaughter RL: *see* Edwards et al, 62
 Slough CL: *see* Yakatan et al, 402
 Sodums MT: *see* Crawford et al, 459
 Sohn YJ: *see* Uges et al, 587
 Somogyi AA: *see* Gugler et al, 501
 Sonders RC: *see* Granneman et al, 95
 Steenland K: *see* Paigen et al, 144
 Stein RS: *see* Hande et al, 669
 Steiness E: Negative potassium balance during beta-blocker treatment of hypertension, 691
 Stewart J: *see* Rangno et al, 564
 Stitzer ML: *see* McCaul et al, 753

Stote R: *see* Dubb et al, 516
Sutfin TA: *see* Potter et al, 393

T

Talbert RL: *see* Yakatan et al, 402
Tang-Liu D D-S, Williams RL, Riegelman S: Non-linear theophylline elimination, 358
Taylor CR: *see* Leier et al, 89
Thien T: *see* Houben et al, 685
Thomas EW: *see* Granneman et al, 95
Thuillez C: *see* Richer et al, 579
Tong TG: *see* Pond et al, 139
Turck M: *see* Counts et al, 662

U

Uges DRA, Sohn YJ, Greijdanus B, Scaf AHJ, Agoston S: 4-Aminopyridine kinetics, 587
Umsawasdi T: *see* Savaraj et al, 312
Upton RA, Williams RL, Buskin JN, Jones RM: Effects of probenecid on ketoprofen kinetics, 705

V

Valdivieso M: *see* Savaraj et al, 321
VanBakel AB: *see* May et al, 656
van Brummelen P: *see* Kiowski et al, 677
Van Echo DA: *see* Bachur et al, 650
van Reenen OR: *see* Muller et al, 339
van't Larr A: *see* Houben et al, 685
Vera Z: *see* Awan et al, 290
Verbeeck RK, Patwardhan RV, Villeneuve J-P, Wilkinson GR, Branch RA: Furosemide disposition in cirrhosis, 719
Verebey K: *see* Inturrisi et al, 157
Vesell ES: On the significance of host factors that affect drug disposition, 1 (Commentary)
—*see* Berlin and Vesell, 38
—*see* Miaskiewicz et al, 30
Vestal RE: *see* Adir et al, 488
Villeneuve J-P: *see* Verbeeck et al, 719
Vinks A, Inaba T, Otton SV, Kalow W: Sparteine metabolism in Canadian Caucasians, 23

W

Wachtel P: *see* Zahler et al, 775
Wagner KF: *see* Counts et al, 662
Walker BR: *see* Chiang et al, 509
Wall ME: *see* Cook et al, 625

Ward E: *see* Paigen et al, 144
Weber MA, Brewer DD, Drayer JIM, Aronow WS, Lipson JL, Ricci BA: A vasodilator that avoids renin stimulation and fluid retention: antihypertensive treatment with trimazosin, 572
Wessel HB: *see* Pitlick et al, 466
Westwood B: *see* Breen et al, 297
Whelton A: *see* Laskin et al, 594
Whitacre M: *see* Bachur et al, 650
Wilensky AJ: *see* Bauer et al, 741
Wilkin JK, Wilkin O, Kapp R, Donachie R, Chernosky M, Buckner J: Aspirin blocks nicotinic acid-induced flushing, 478
Wilkin O: *see* Wilkin et al, 478
Wilkinson GR: *see* Verbeeck et al, 719
Willard DA: *see* Duchin et al, 452
Williams WM: *see* May et al, 656
Williams RL: *see* Tang-Liu et al, 358
—*see* Upton et al, 705
Wilson JD: *see* Booth et al, 555
Winkle RA: *see* Kates et al, 427
Wolff SN: *see* Hande et al, 669
Wolfram KM: *see* Bjornsson et al, 104
—*see* Mahony et al, 330
Wolshin EM: *see* Ronfeld et al, 384
Wood AW: *see* Paigen et al, 144
Woody GE: *see* Inturrisi et al, 157
Woolhouse NM, Atu-Taylor LC: Influence of double genetic polymorphism on response to sulfamethazine, 377
Wynne B: *see* Granneman et al, 95

Y

Yakatan GJ, Poynor WJ, Talbert RL, Floyd BF, Slough CL, Ampulski RS, Benedict JJ: Clodronate kinetics and bioavailability, 402

Z

Zahler R, Wachtel P, Jatlow P, Byck R: Kinetics of drug effect by distributed lags analysis: an application to cocaine, 775
Zamboulis C: *see* Brown et al, 16
Zavadil AP III: *see* Kitanaka et al, 51
—*see* Potter et al, 393
Zech PY: *see* Chau et al, 770
Zekorn C: *see* Eichelbaum et al, 184

Subject index

A

- Absorption kinetics of sodium salicylate, sex differences in (Miaskiewicz et al), 30
- Acetaminophen disposition, obesity, and sex (Abernethy et al), 783
 - kinetics in the elderly (Divoll et al), 151
- N*-Acetylprocainamide in heart disease, hemodynamic effects of (Crawford et al), 459
 - kinetics after single and repeated oral doses (Ludden and Crawford), 343
- Acid, α_1 -, glycoprotein concentration and protein binding in trauma (Edwards et al), 62
 - inhibition, gastric, and oxmetidine kinetics in duodenal ulcer (Gugler et al), 501
 - modulated variations, nonfatty, in drug binding due to heparin (Naranjo et al), 746
 - nicotinic, induced flushing, aspirin blocks (Wilkin et al), 478
 - valproic, possible interaction with: ethosuximide kinetics (Bauer et al), 741
- Acyclovir kinetics in end-stage renal disease (Laskin et al), 594
- Addicts, methadone-maintained, lack of effect of diazepam on methadone metabolism in (Pond et al), 139
- Adrenergic-receptor blockers, β -, and antinuclear antibodies in hypertension (Booth et al), 555
- Age and phenytoin kinetics in adult epileptics (Bauer and Blouin), 301
 - and renal clearance of cimetidine (Drayer et al), 45
 - and total plasma concentration, effects of, on tolbutamide plasma protein binding (Adir et al), 488
- Airflow obstruction, chronic, and bronchial asthma, theophylline kinetics and ventilatory flow in: influence of erythromycin (Richer et al), 579
- Alcohol and coffee and caffeine effects on psychomotor function (Nuotto et al), 68
- Aldosteronism, primary, amiloride in (Griffing et al), 56
- α_1 -acid glycoprotein concentration and protein binding in trauma (Edwards et al), 62
- Alterations in propylthiouracil disposition, mechanism of, after long-term therapy (Giles et al), 559
- American Society for Clinical Pharmacology and Therapeutics, abstracts of papers, 198

ASCPT—cont'd

- meeting program, 119
- message from president, 118
- notes of, 116, 793
- Amiloride in Barter's syndrome (Griffing et al), 713
 - in primary aldosteronism (Griffing et al), 56
 - and spironolactone in healthy man, relative potency of (McInnes), 472
- 4-Aminopyridine kinetics (Uges et al), 587
- Amiodarone kinetics after oral doses (Kannan et al), 438
- Amitriptyline metabolites, *cis*- and *trans*-10-OH, steady-state plasma concentrations of (Bock et al), 609
- Antacids, effect of in steady-state plasma desmethyldiazepam during long-term clorazepate use (Shader et al), 180
- 9,10-Anthracenedione, 1,4-dihydroxy-5,8-bis [[2-[2-hydroxyethyl]amino]ethyl]amino], clinical kinetics of, (Savaraj et al), 312
- Antibodies, antinuclear, and β -adrenergic-receptor blockers in hypertension (Booth et al), 555
- Anticholinergics, oral, and gastric emptying (Hurtwitz et al), 168
- Antidiarrheal drugs, a simple controlled method for the clinical evaluation of (LaCorte et al), 766
- Antihypertensive and renal effects of captopril in relation to renin activity and bradykinin-induced vasodilation (Kiowski et al), 677
 - treatment with trimazosin: vasodilator that avoids renin stimulation and fluid retention (Weber et al), 572
- Antinuclear antibodies and β -adrenergic-receptor blockers in hypertension (Booth et al), 555
- Antipyrine disposition in milk and saliva of lactating women (Berlin and Vesell), 38
 - metabolism, absence of seasonal variation in (Paigen et al), 144
- Arthritis, rheumatoid, relationship of serum naproxen concentration to efficacy in (Day et al), 733
- Aspirin blocks nicotinic acid-induced flushing (Wilkin et al), 478
 - and valproic acid in epileptic children, interaction between: serum protein binding and metabolic effects (Orr et al), 642
- Assay methods, three, heparin kinetics determined by (Bjornsson et al), 104
- Associates of Clinical Pharmacology, meeting program, 138

Asthma, bronchial, and chronic airflow obstruction, theophylline kinetics and ventilatory flow in: influence of erythromycin (Richer et al), 579

B

- Balance, potassium, in piritanide and digoxin treatment (Muller et al), 339
- Barter's syndrome, amiloride in (Griffing et al), 713
- Beta-adrenergic-receptor blockers and antinuclear antibodies in hypertension (Booth et al), 555
- blockade in hypertension, effect of low-dose epinephrine infusion on hemodynamics after selective and nonselective (Houben et al), 685
- short-term, effects of on blood pressure, plasma thromboxane B_2 , and plasma and urinary prostaglandins E_2 and $F_{2\alpha}$ in normal subjects (Graham et al), 324
- blocker treatment of hypertension, negative potassium balance during (Steiness), 691
- Biliary excretion of drugs in man, quantitation of (Dujovne et al), 187
- Binding of phencyclidine, plasma protein (Giles et al), 77
- protein, and alpha₁-acid glycoprotein concentration in trauma (Edwards et al), 62
- serum protein, and metabolic effects: interaction between valproic acid and aspirin in epileptic children (Orr et al), 642
- Bioavailability and kinetics of clodronate (Yakatan et al), 402
- Blockade, β -, in hypertension, effect of low-dose epinephrine infusion on hemodynamics after selective and nonselective (Houben et al), 685
- short-term, effects of, on blood pressure, plasma thromboxane B_2 , and plasma and urinary prostaglandins E_2 and $F_{2\alpha}$ in normal subjects (Graham et al), 324
- Blocker(s), beta, treatment of hypertension, negative potassium balance during (Steiness), 691
- receptor, β -adrenergic-, and antinuclear antibodies in hypertension (Booth et al), 555
- Blood levels, choline, free and bound, after phosphatidylcholine (Jope et al), 483
- pressure, catecholamines, and renin activity during long-term treatment of hypertension, plasma clonidine in relation to (Manhem et al), 445
- plasma thromboxane B_2 , and plasma and urinary prostaglandins E_2 and $F_{2\alpha}$ in normal subjects, effects of short-term beta blockade on (Graham et al), 324
- Bound and free choline blood levels after phosphatidylcholine (Jope et al), 483
- Bradykinin-induced vasodilation, antihypertensive and renal effects of captopril in relation to renin activity and (Kiowski et al), 677

Bronchial asthma and chronic airflow obstruction, theophylline kinetics and ventilatory flow in: influence of erythromycin (Richer et al), 579

C

- Caffeine and coffee and alcohol effects on psychomotor function (Nuotto et al), 68
- disposition in smokers and nonsmokers, effects of cimetidine on (May et al), 656
- Canadian Caucasians, sparteine metabolism in (Vinks et al), 23
- Captopril, antihypertensive and renal effects of, in relation to renin activity and bradykinin-induced vasodilation (Kiowski et al), 677
- converting enzyme inhibition with, in patients with primary hyperaldosteronism (Luderer et al), 305
- kinetics (Duchin et al), 452
- Cardiac efficacy of elevated serum digoxin concentration: quinidine-digoxin interaction (Belz et al), 548
- hyper- and hyposponsiveness after pindolol withdrawal (Rangno et al), 564
- Cardiocirculatory actions of trimazosin and sodium nitroprusside in ischemic heart disease (Awan et al), 290
- Catecholamines, blood pressure, and renin activity during long-term treatment of hypertension, plasma clonidine in relation to (Manhem et al), 445
- Caucasians, Canadian, sparteine metabolism in (Vinks et al), 23
- Cefsulodin kinetics in healthy subjects after intramuscular and intravenous injection (Granneman et al), 95
- in renal impairment (Gibson et al), 602
- Ceftizoxime kinetics and renal handling (Dubb et al), 516
- Cerebrospinal fluid and equilibrium dialysis, zimeclidine and norzimeclidine protein binding measured by (Calil et al), 522
- and plasma kinetics of diaziquone, 2,5-diaziridinyl-3,6-biscarboethoxyamino-1,4-benzoquinone (Bachur et al), 650
- Children, epileptic, interaction between valproic acid and aspirin in: serum protein binding and metabolic effects (Orr et al), 642
- moxalactam epimer kinetics in (Nahata et al), 528
- Chlorpromazine disposition and actions, cigarette smoking and (Pantuck et al), 533
- Choline blood levels, free and bound, after phosphatidylcholine (Jope et al), 483
- Chronic airflow obstruction and bronchial asthma, theophylline kinetics and ventilatory flow in: influence of erythromycin (Richer et al), 579
- Cigarette(s), marihuana, of three different potencies, comparison of effects of (Perez-Reyes et al), 617

- Cigarette(s)—cont'd
 smoking and chlorpromazine disposition and actions (Pantuck et al), 533
- Cimetidine, age and renal clearance of (Drayer et al), 45
 dynamics after single intravenous doses (Pancorbo et al), 83
 effects of, on caffeine disposition in smokers and nonsmokers (May et al), 656
 and ranitidine, effects of, on hepatic drug metabolism (Breen et al), 297
- Cirrhosis, furosemide disposition in (Verbeeck et al), 719
- Clearance, renal, age and, of cimetidine (Drayer et al), 45
- Clinical Pharmacology and Therapeutics, American Society for: *see* American Society for Clinical Pharmacology and Therapeutics
- Clodronate kinetics and bioavailability (Yakatan et al), 402
- Clonidine, plasma, in relation to blood pressure, catecholamines, and renin activity during long-term treatment of hypertension (Manhem et al), 445
- Clorazepate use, long-term, steady-state plasma desmethyldiazepam during: effect of antacids (Shader et al), 180
- Cocaine, an application to: kinetics of drug effects by distributed lags analysis (Zahler et al), 775
- Coffee and caffeine and alcohol effects on psychomotor function (Nuotto et al), 68
- Controlled method, simple, for the clinical evaluation of antidiarrheal drugs (LaCorte et al), 766
- Converting enzyme inhibition with captopril in patients with primary hyperaldosteronism (Luderer et al), 305
- Cytarabine, high-dose, effects of (Hande et al), 669

D

- Debrisoquine and sparteine, polymorphic oxidation of: related pharmacogenetic entities (Eichelbaum et al), 184
- Depressed patients, elderly, altered hydroxydesipramine concentrations in (Kitanaka et al), 51
- Desipramine and imipramine, active metabolites of, in man (Potter et al), 393
- Desmethyldiazepam, steady-state plasma, during long-term clorazepate use: effect of antacids (Shader et al), 180
- Diabetics, kinetics of subcutaneous NPH insulin in (Køglendørf and Bojsen), 494
- Dialysis, equilibrium, and cerebrospinal fluid, zimeidine and norzimeidine protein binding measured by (Calil et al), 522
- Diazepam and lidocaine plasma protein binding in renal disease (Grossman et al), 350

- Diazepam—cont'd
 on methadone metabolism in methadone-maintained addicts, lack of effect of (Pond et al), 139
- Diaziquone, 2,5-diaziridinyl-3,6-biscarboethoxy-amino-1,4-benzoquinone, plasma and cerebrospinal fluid kinetics (Bachure et al), 650
- 2,5-Diaziridinyl-3,6-biscarboethoxyamino-1,4-benzoquinone, diaziquone, plasma and cerebrospinal fluid kinetics (Bachure et al), 650
- Digoxigenin transformation (Gault et al), 695
- Digoxin concentration, erythrocyte (Kawai et al), 541
 serum, cardiac efficacy of elevated: quinidine-digoxin interaction (Belz et al), 548
 and piritanide treatment, potassium balance in (Muller et al), 339
 -quinidine interaction: cardiac efficacy of elevated serum digoxin concentration (Belz et al), 548
- 1,4-Dihydroxy-5,8-bis[[3-[(2-hydroxyethyl)amino]ethyl]amino]-9,10-anthracenedione, clinical kinetics of (Savaraj et al), 312
- Dipyridamole kinetics (Mahony et al), 330
- Disposition: *see also* specific drug
- Disposition, drug, on the significance of host factors that affect (Vesell), 1 (Commentary)
- Distributed lags analysis, kinetics of drug effect by: application to cocaine (Zahler et al), 775
- Diuretics, hemodynamic effects of, in patients with marked peripheral edema and mild hypertension (Niarchos and Magrini), 370
- Dose-response relationships for spironolactone at steady state (McInnes et al), 317
- Double genetic polymorphism, influence of, on response to sulfamethazine (Woolhouse and Atu-Taylor), 377
- Drug(s): *see also* specific drug name
- Drug(s), antidiarrheal, a simple controlled method for the clinical evaluation of (LaCorte et al), 766
 binding due to heparin, nonfatty acid-modulated variations in (Naranjo et al), 746
 disposition, on the significance of host factors that affect (Vesell), 1 (Commentary)
 effect by distributed lags analysis, kinetics of: an application to cocaine (Zahler et al), 775
 metabolism, hepatic, effects of cimetidine and ranitidine on (Breen et al), 297
 new, will all become orphans? (Lasagna), 285 (Commentary)
 quantitation of biliary excretion of, in man (Dujovne et al), 187
- Duodenal ulcer, gastric acid inhibition and omepridine kinetics in (Gugler et al), 501
- Dynamics: *see* specific drug

E

- Edema, peripheral, and mild hypertension, hemodynamic effects of diuretics in patients with marked (Niarchos and Magrini), 370

- Efficacy, cardiac, of elevated serum digoxin concentration: quinidine-digoxin interaction (Belz et al), 548
- Elderly, acetaminophen kinetics in the (Divoll et al), 151
- depressed patients, altered hydroxydesipramine concentrations in (Kitanaka et al), 51
- Elimination, nonlinear theophylline (Tang-Liu et al), 358
- Encainide administration, oral, long-term, metabolite cumulation during (Kates et al), 427
- End-stage renal disease, acyclovir kinetics in (Laskin et al), 594
- Enzyme inhibition, converting, with captopril in patients with primary hyperaldosteronism (Luderer et al), 305
- Epileptic(s), adult, age and phenytoin kinetics in (Bauer and Blouin), 301
- children, interaction between valproic acid and aspirin in: serum protein binding and metabolic effects (Orr et al), 642
- Epimer kinetics, moxalactam, in children (Nahata et al), 528
- Epinephrine infusion, low-dose, effect of, on hemodynamics after selective and nonselective β -blockade in hypertension (Houben et al), 685
- Equilibrium dialysis and cerebrospinal fluid, zimeldine and norzimeldine protein binding measured by (Calil et al), 522
- Erythrocyte digoxin concentration (Kawai et al), 541
- Erythromycin, influence of: theophylline kinetics and ventilatory flow in bronchial asthma and chronic airflow obstruction (Richer et al), 579
- Essential hypertension, estimation of sympathetic activity in (Brown et al), 16
- Ethosuximide kinetics: possible interaction with valproic acid (Bauer et al), 741
- Excretion, biliary, of drugs in man, quantitation of (Dujovne et al), 187
- Extrapulmonary effects of terbutaline during prolonged administration (Bengtsson and Fagerstrom), 726

F

- Fluid retention and renin stimulation, vasodilator that avoids: antihypertensive treatment with trimazosin (Weber et al), 572
- Flushing, nicotinic acid-induced, aspirin blocks (Wilkin et al), 478
- Free and bound choline blood levels after phosphatidylcholine (Jope et al), 483
- Furosemide disposition in cirrhosis (Verbeeck et al), 719

G

- Gastric acid inhibition and oxmetidine kinetics in duodenal ulcer (Gugler et al), 501
- emptying and oral anticholinergics (Hurwitz et al), 168

- Genetic polymorphism, double, influence of, on response to sulfamethazine (Woolhouse and Atu-Taylor), 377
- Gentamicin and tobramycin kinetics (Counts et al), 662
- Glycerol and hyperosmolality, effects of, on intracranial pressure (Pitlick et al), 466
- Glycoprotein concentration, α_1 -acid, and protein binding in trauma (Edwards et al), 62

H

- Healthy man, relative potency of amiloride and spironolactone in (McInnes), 472
- Heart disease, hemodynamic effects of *N*-acetylprocainamide in (Crawford et al), 459
- ischemic, cardiocirculatory actions of trimazosin and sodium nitroprusside in (Awan et al), 290
- Hemodynamic(s) effects of *N*-acetylprocainamide in heart disease (Crawford et al), 459
- of diuretics in patients with marked peripheral edema and mild hypertension (Niarchos and Magrini), 370
- effect of low-dose epinephrine infusion on, after selective and nonselective β -blockade in hypertension (Houben et al), 685
- Heparin kinetics determined by three assay methods (Bjornsson et al), 104
- nonfatty acid-modulated variations in drug binding due to (Naranjo et al), 746
- Hepatic drug metabolism, effects of cimetidine and ranitidine on (Breen et al), 297
- High-dose cytarabine, effects of (Hande et al), 669
- Host factors that affect drug disposition, on the significance of (Vesell), 1 (Commentary)
- Hydroxydesipramine concentrations, altered, in elderly depressed patients (Kitanaka et al), 51
- Hyperaldosteronism, primary, converting enzyme inhibition with captopril in patients with (Luderer et al), 305
- Hyperosmolality and glycerol, effects of, on intracranial pressure (Pitlick et al), 466
- Hyperresponsiveness and hyporesponsiveness, cardiac, after pindolol withdrawal (Rangno et al), 564
- Hypertension, β -adrenergic-receptor blockers and antinuclear antibodies in (Booth et al), 555
- essential, estimation of sympathetic activity in (Brown et al), 16
- long-term treatment of, plasma clonidine in relation to blood pressure, catecholamines, and renin activity during (Manhem et al), 445
- mild, and marked peripheral edema, hemodynamic effects of diuretics in patients with (Niarchos and Magrini), 370
- negative potassium balance during beta-blocker treatment of (Steiness), 691

Hypertension—cont'd

selective and nonselective β -blockade in, effect of low-dose epinephrine infusion on hemodynamics after (Houben et al), 685

Hyporesponsiveness and hyperresponsiveness, cardiac, after pindolol withdrawal (Rangno et al), 564

I

Imipramine and desipramine in man, active metabolites of (Potter et al), 393

Infusion(s), long-term, influence of, on lidocaine kinetics (Bauer et al), 433

low-dose epinephrine, effect of, on hemodynamics after selective and nonselective β -blockade in hypertension (Houben et al), 685

Inhibition, converting enzyme, with captopril in patients with primary hyperaldosteronism (Luderer et al), 305

Insulin, subcutaneous NPH, in diabetics, kinetics of (Køllendorf and Bojsen), 494

Intracranial pressure, effects of glycerol and hyperosmolality on (Pitlick et al), 466

Intramuscular and intravenous injection, cefsulodin kinetics in healthy subjects after (Granneman et al), 95

Intravenous doses, single, cimetidine dynamics after (Pancorbo et al), 83

and intramuscular injection, cefsulodin kinetics in healthy subjects after (Granneman et al), 95

and oral doses, phencyclidine disposition after (Cook et al), 625

single, of verapamil, kinetic and dynamic effects after. IV. The pharmacology of verapamil (McAllister and Kirsten), 418

pirbuterol (Leier et al), 89

Ischemic heart disease, cardiocirculatory actions of trimazosin and sodium nitroprusside in (Awan et al), 290

K

Ketoprofen kinetics, effects of probenecid on (Upton et al), 705

Kinetics: *see also* specific drug

Kinetics, absorption, of sodium salicylate, sex differences in (Miaskiewicz et al), 30

L

Lactating women, antipyrine disposition in milk and saliva of (Berlin and Vesell), 38

Lags analysis, distributed, kinetics of drug effect by: an application to cocaine (Zahler et al), 775

Lidocaine and diazepam plasma protein binding in renal disease (Grossman et al), 350

kinetics, influence of long-term infusions on (Bauer et al), 433

Lorazepam—efficacy, side effects, and rebound phenomena (Scharf and Jacoby), 175

Low-dose epinephrine infusion, effect of, on hemodynamics after selective and nonselective β -blockade in hypertension (Houben et al), 685

M

Maintenance subjects, methadone, short-term effects of oral methadone in (McCaul et al), 753

Marihuana cigarettes of three different potencies, comparison of effects of (Perez-Reyes et al), 617

Medication usage, nondichotomous patterns of: the yes-no fallacy (Dirks and Kinsman), 413 (Commentary)

Metabolic effects and serum protein binding: interaction between valproic acid and aspirin in epileptic children (Orr et al), 642

Metabolism, antipyrine, absence of seasonal variation in (Paigen et al), 144

hepatic drug, effects of cimetidine and ranitidine on (Breen et al), 297

methadone, in methadone-maintained addicts, lack of effect of diazepam on (Pond et al), 139

sparteine, in Canadian Caucasians (Vinks et al), 23

Metabolite(s), active, of imipramine and desipramine in man (Potter et al), 393

amitriptyline, *cis*- and *trans*-10-OH, steady-state plasma concentrations of (Bock et al), 609

cumulation during long-term oral encainide administration (Kates et al), 427

tocainide, and tocainide, on the kinetics and dynamics of (Ronfeld et al), 384

Methadone-maintained addicts, lack of effect of diazepam on methadone metabolism in (Pond et al), 139

metabolism in methadone-maintained addicts, lack of effect of diazepam on (Pond et al), 139

oral, in methadone maintenance subjects, short-term effects of (McCaul et al), 753

Metoprolol withdrawal phenomena: mechanism and prevention (Rangno et al), 8

Mild hypertension and marked peripheral edema, hemodynamic effects of diuretics in patients with (Niarchos and Magrini), 370

Milk and saliva of lactating women, antipyrine disposition in (Berlin and Vesell), 38

Moxalactam epimer kinetics in children (Nahata et al), 528

N

Naproxen concentration, serum, relationship of, to efficacy in rheumatoid arthritis (Day et al), 733

Negative potassium balance during beta-blocker treatment of hypertension (Steiness), 691

Nicotinic acid—induced flushing, aspirin blocks (Wilkin et al), 478

- Nondichotomous patterns of medication usage: the yes-no fallacy (Dirks and Kinsman), 413 (Commentary)
- Nonfatty acid-modulated variations in drug binding due to heparin (Naranjo et al), 746
- Nonlinear theophylline elimination (Tang-Liu et al), 358
- Nonselective and selective β -blockade in hypertension, effect of low-dose epinephrine infusion on hemodynamics after (Houben et al), 685
- Nonsmokers and smokers, effects of cimetidine on caffeine disposition in (May et al), 656
- Normal subjects, ranitidine kinetics in (Chau et al), 770
- Norpropoxyphene and propoxyphene kinetics after single and repeated doses of propoxyphene (Inturrisi et al), 157
- Norzimelidine and zimelidine protein binding measured by equilibrium dialysis and cerebrospinal fluid (Calil et al), 522
- NPH insulin, subcutaneous, in diabetics, kinetics of (Kølerdorf and Bojsen), 494

O

- Obesity, sex, and acetaminophen disposition (Abernethy et al), 783
- Oral anticholinergics and gastric emptying (Hurwitz et al), 168
- doses, amiodarone kinetics after (Kannan et al), 438
- single and repeated, *N*-acetylprocainamide kinetics after (Ludden and Crawford), 343
- encainide administration, long-term, metabolite cumulation during (Kates et al), 427
- and intravenous doses, phencyclidine disposition after (Cook et al), 625
- single, of verapamil, kinetic and dynamic effects after. IV. The pharmacology of verapamil (McAllister and Kirsten), 418
- methadone in methadone maintenance subjects, short-term effects of (McCaul et al), 753
- Orphans, will all new drugs become? (Lasagna), 285 (Commentary)
- Oxaprozin disposition in renal disease (Chiang et al), 509
- Oxidation, polymorphic, of sparteine and debrisoquine: related pharmacogenetic entities (Eichelbaum et al), 184
- Oxmetidine kinetics and gastric acid inhibition in duodenal ulcer (Gugler et al), 501

P

- Peripheral edema and mild hypertension, hemodynamic effects of diuretics in patients with marked (Niarchos and Magrini), 370
- Pharmacogenetic entities, related: polymorphic oxidation of sparteine and debrisoquine (Eichelbaum et al), 184

- Pharmacology and Therapeutics, Clinical, American Society for: see American Society for Clinical Pharmacology and Therapeutics
- Phencyclidine disposition after intravenous and oral doses (Cook et al), 625
- and phenylcyclohexane disposition after smoking phencyclidine (Cook et al), 635
- plasma protein binding of (Giles et al), 77
- Phenylcyclohexene and phencyclidine disposition after smoking phencyclidine (Cook et al), 635
- Phenytoin kinetics and age in adult epileptics (Bauer and Blouin), 301
- removal by plasmapheresis in thrombotic thrombocytopenic purpura (Liu and Rubenstein), 762
- Phosphatidylcholine, free and bound choline blood levels after (Ito et al), 483
- Pindolol withdrawal, cardiac hyper- and hyporesponsiveness after (Rangno et al), 564
- Pirbuterol, intravenous (Leier et al), 89
- Piretanide and digoxin treatment, potassium balance in (Muller et al), 339
- Plasma and cerebrospinal fluid kinetics of diaziquone, 2,5-diaziridinyl-3,6-biscarboethoxyamino-1,4-benzoquinone (Bachur et al), 650
- clonidine in relation to blood pressure, catecholamines, and renin activity during long-term treatment of hypertension (Manhem et al), 445
- concentration(s), total, and age, effects of, on tolbutamide plasma protein binding (Adir et al), 488
- steady-state, of *cis*- and *trans*-10-OH amitriptyline metabolites (Bock et al), 609
- protein binding in renal disease, lidocaine and diazepam (Grossman et al), 350
- thromboxane B_2 , blood pressure, and plasma and urinary prostaglandins E_2 and $F_{2\alpha}$ in normal subjects, effects of short-term beta blockade on (Graham et al), 324
- and urinary prostaglandins E_2 and $F_{2\alpha}$ in normal subjects, effects of short-term beta blockade on blood pressure, plasma thromboxane B_2 , and (Graham et al), 324
- Plasmapheresis, phenytoin removal by, in thrombotic thrombocytopenic purpura (Liu and Rubenstein), 762
- Polymorphic oxidation of sparteine and debrisoquine: related pharmacogenetic entities (Eichelbaum et al), 184
- Polymorphism, double genetic, influence of, on response to sulfamethazine (Woolhouse and Atu-Taylor), 377
- Potassium balance, negative, during beta-blocker treatment of hypertension (Steiness), 691
- in piretanide and digoxin treatment (Muller et al), 339

- Potencies, three different, comparison of effects of marihuana cigarettes of (Perez-Reyes et al), 617
- Primary aldosteronism, amiloride in (Griffing et al), 56
- hyperaldosteronism, converting enzyme inhibition with captopril in patients with (Luderer et al), 305
- Probenecid, effects of, on ketoprofen kinetics (Upton et al), 705
- Propoxyphene and norpropoxyphene kinetics after single and repeated doses of propoxyphene (Inturrisi et al), 157
- Propylthiouracil disposition after long-term therapy, mechanism of alterations in (Giles et al), 559
- Prostaglandins E_2 and $F_{2\alpha}$, plasma and urinary, in normal subjects, effects of short-term beta blockade on blood pressure, plasma thromboxane B_2 , and (Graham et al), 324
- Protein binding and alpha₁-acid glycoprotein concentration in trauma (Edwards et al), 62
- lidocaine and diazepam plasma, in renal disease (Grossman et al), 350
- norzimelidine and zimelidine, measured by equilibrium dialysis and cerebrospinal fluid (Calil et al), 522
- plasma, of phencyclidine (Giles et al), 77
- serum, and metabolic effects: interaction between valproic acid and aspirin in epileptic children (Orr et al), 642
- tolbutamide plasma, effects of total plasma concentration and age on (Adir et al), 488
- Psychomotor function, coffee and caffeine and alcohol effects on (Nuotto et al), 68
- Purpura, thrombotic thrombocytopenic, phenytoin removal by plasmapheresis in (Liu and Rubenstein), 762

Q

- Quantitation of biliary excretion of drugs in man (Dujovne et al), 187
- Quinidine-digoxin interaction: cardiac efficacy of elevated serum digoxin concentration (Belz et al), 548

R

- Ranitidine and cimetidine, effects of, on hepatic drug metabolism (Breen et al), 297
- kinetics in normal subjects (Chau et al), 770
- Rebound phenomena, side effects, and efficacy of lorazepam (Scharf and Jacoby), 175
- Receptor blockers, β -adrenergic-, and antinuclear antibodies in hypertension (Booth et al), 555
- Renal and antihypertensive effects of captopril in relation to renin activity and bradykinin-induced vasodilation (Kiowski et al), 677

Renal—cont'd

- clearance, age and, of cimetidine (Drayer et al), 45
- disease, diazepam and lidocaine plasma protein binding in (Grossman et al), 350
- end-stage, acyclovir kinetics in (Laskin et al), 594
- oxaprozin disposition in (Chiang et al), 509
- handling and ceftizoxime kinetics (Dubb et al), 516
- impairment, cefsulodin kinetics in (Gibson et al), 602
- Renin activity, blood pressure, and catecholamines during long-term treatment of hypertension, plasma clonidine in relation to (Manhem et al), 445
- and bradykinin-induced vasodilation, antihypertensive and renal effects of captopril in relation to (Kiowski et al), 677
- stimulation and fluid retention, vasodilator that avoids: antihypertensive treatment with trimazosin (Weber et al), 572
- Rheumatoid arthritis, relationship of serum naproxen concentration to efficacy in (Day et al), 733

S

- Salicylate, sodium, sex differences in absorption kinetics of (Miaskiewicz et al), 30
- Saliva and milk of lactating women, antipyrine disposition in (Berlin and Vesell), 38
- Seasonal variation in antipyrine metabolism, absence of (Paigen et al), 144
- Selective and nonselective β -blockade in hypertension, effect of low-dose epinephrine infusion on hemodynamics after (Houben et al), 685
- Serum digoxin concentration, elevated, cardiac efficacy of: quinidine-digoxin interaction (Belz et al), 548
- naproxen concentration, relationship of, to efficacy in rheumatoid arthritis (Day et al), 733
- protein binding and metabolic effects: interaction between valproic acid and aspirin in epileptic children (Orr et al), 642
- Sex differences in absorption kinetics of sodium salicylate (Miaskiewicz et al), 30
- obesity, and acetaminophen disposition (Abernethy et al), 783
- Side effects, efficacy, and rebound phenomena of lorazepam (Scharf and Jacoby), 175
- Smokers and nonsmokers, effects of cimetidine on caffeine disposition in (May et al), 656
- Smoking, cigarette, and chlorpromazine disposition and actions (Pantuck et al), 533
- phencyclidine, phencyclidine and phenylcyclohexene disposition after (Cook et al), 635
- Sodium nitroprusside and trimazosin in ischemic heart disease, cardiocirculatory actions of (Awan et al), 290

Sodium—cont'd

- salicylate, sex differences in absorption kinetics of (Miaskiewicz et al), 30
- Sparteine and debrisoquine, polymorphic oxidation of: related pharmacogenetic entities (Eichelbaum et al), 184
- metabolism in Canadian Caucasians (Vinks et al), 23
- Spirolactone and amiloride, relative potency of, in healthy man (McInnes), 472
- at steady state, dose-response relationships for (McInnes et al), 317
- Steady state, dose-response relationships for spironolactone at (McInnes et al), 317
- plasma concentrations of *cis*- and *trans*-10-OH amitriptyline metabolites (Bock et al), 609
- desmethyldiazepam during long-term clorazepate use: effect of antacids (Shader et al), 180
- Stimulation, renin, and fluid retention, vasodilator that avoids: antihypertensive treatment with trimazosin (Weber et al), 572
- Subcutaneous NPH insulin in diabetics, kinetics of (Køglund and Bojsen), 494
- Sulfamethazine, influence of double genetic polymorphism on response to (Woolhouse and Atu-Taylor), 377
- Sympathetic activity in essential hypertension, estimation of (Brown et al), 16

T

- Terbutaline during prolonged administration, extrapulmonary effects of (Bengtsson and Fagerstrom), 726
- Theophylline elimination, nonlinear (Tang-Liu et al), 358
- kinetics and ventilatory flow in bronchial asthma and chronic airflow obstruction: influence of erythromycin (Richer et al), 579
- Therapeutics, and Pharmacology, Clinical, American Society for: see American Society for Clinical Pharmacology and Therapeutics
- Therapy, long-term, mechanism of alterations in propylthiouracil disposition after (Giles et al), 559
- Thrombocytopenic purpura, thrombotic, phenytoin removal by plasmapheresis in (Liu and Rubenstein), 762
- Thrombotic thrombocytopenic purpura, phenytoin removal by plasmapheresis in (Liu and Rubenstein), 762
- Tobramycin and gentamicin kinetics (Counts et al), 662
- Tocainide and its metabolites, on the kinetics and dynamics of (Ronfeld et al), 384
- Tolbutamide plasma protein binding, effects of total plasma concentration and age on (Adir et al), 488

- Transformation, digoxigenin (Gault et al), 695
- Trauma, alpha₁-acid glycoprotein concentration and protein binding in (Edwards et al), 62
- Trimazosin, antihypertensive treatment with: vasodilator that avoids renin stimulation and fluid retention (Weber et al), 572
- and sodium nitroprusside in ischemic heart disease, cardiocirculatory actions of (Awan et al), 290

U

- Ulcer, duodenal, gastric acid inhibition and oximetidine kinetics in (Gugler et al), 501
- Urinary and plasma prostaglandins E₂ and F_{2α} in normal subjects, effects of short-term beta blockade on blood pressure, plasma thromboxane B₂, and (Graham et al), 324
- USAN Council list of new names, 114, 195, 411, 539, 675, 791

V

- Valproic acid and aspirin in epileptic children, interaction between: serum protein binding and metabolic effects (Orr et al), 642
- possible interaction with: ethosuximide kinetics (Bauer et al), 741
- Vasodilation, bradykinin-induced, antihypertensive and renal effects of captopril in relation to renin activity and (Kiowski et al), 677
- Vasodilator that avoids renin stimulation and fluid retention: antihypertensive treatment with trimazosin (Weber et al), 572
- Ventilatory flow and theophylline kinetics in bronchial asthma and chronic airflow obstruction: influence of erythromycin (Richer et al), 579
- Verapamil, pharmacology of. IV. Kinetic and dynamic effects after single intravenous and oral doses (McAllister and Kirsten), 418

W

- Withdrawal phenomena, metoprolol: mechanism and prevention (Rangno et al), 8
- pindolol, cardiac hyper- and hyporesponsiveness after (Rangno et al), 564

Y

- Yes-no fallacy of nondichotomous patterns of medication usage (Dirks and Kinsman), 413 (Commentary)

Z

- Zimelidine and norzimelidine protein binding measured by equilibrium dialysis and cerebrospinal fluid (Calil et al), 522

